Inovio Pharmaceuticals (NASDAQ:INO) Announces Earnings Results, Beats Estimates By $0.15 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Positive Sentiment: INO-3107’s FDA review remains on track for the October 30, 2026 PDUFA date; late-cycle review and pre-licensure inspections are complete, with only one reported inspection observation that the company believes it has addressed.
• Positive Sentiment: Inovio is advancing launch preparations for INO-3107, including label negotiations expected to begin in September, medical science liaison activities, and a commercialization agreement with Syneos Health. If approved, the company expects seven years of orphan-drug market exclusivity.
• Negative Sentiment: The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, and feedback on the confirmatory-trial design remains outstanding. The company continues to characterize approval and launch timing as potential outcomes rather than assured results.
• Negative Sentiment: Inovio ended the quarter with $36.7 million in cash, cash equivalents, and short-term investments, and expects approximately $18 million of operational net cash burn in Q3. July’s $18.3 million equity offering extends funding into late Q1 2027 and through a potential launch, but the company noted that this projection excludes future capital raises.
• Positive Sentiment: Partner ApolloBio reported positive pivotal Phase III results for VGX-3100 in cervical dysplasia, meeting its primary efficacy endpoint and supporting plans for a potential regulatory filing in China. Inovio also reported encouraging preclinical progress for its DPROT platform in hemophilia A and other rare diseases.

Inovio Pharmaceuticals Stock Performance

INO traded up $0.00 on Wednesday, hitting $0.77. The company had a trading volume of 3,060,340 shares, compared to its average volume of 2,293,542. The stock has a market capitalization of $63.35 million, a price-to-earnings ratio of -0.53 and a beta of 1.52. The stock has a fifty day moving average price of $1.04 and a 200-day moving average price of $1.31. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on INO. HC Wainwright cut their price target on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating on the stock in a report on Monday, June 1st. Piper Sandler reissued an “overweight” rating and issued a $4.00 price objective on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Wall Street Zen downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, June 21st. Finally, Weiss Ratings raised shares of Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.25.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Inovio Pharmaceuticals in the fourth quarter worth about $77,000. Janus Henderson Group PLC raised its position in shares of Inovio Pharmaceuticals by 1.3% in the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock valued at $5,773,000 after purchasing an additional 42,146 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth about $301,000. 683 Capital Management LLC purchased a new stake in Inovio Pharmaceuticals in the fourth quarter valued at approximately $433,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $388,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.